<DOC>
	<DOCNO>NCT00504556</DOCNO>
	<brief_summary>This study ass safety potential new drug DU-176b prevention stroke/systemic embolic event ( SEE ) individual non-valvular atrial fibrillation ( AF ) . The duration 3 month treatment 30 day follow-up visit .</brief_summary>
	<brief_title>A Study Assess Safety Potential New Drug Comparison Standard Practice Dosing With Warfarin Non-valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Male female , 18 80 year old . 2 . Able provide write informed consent . 3 . Persistent nonvalvular AF support abnormal electrocardiogram ( ECG ) 4 . A congestive heart failure , hypertension , age â‰¥ 75 year , diabetes , prior stroke ( CHADS2 ) index score least 2 1 . Subjects mitral valve disease previous valvular heart surgery 2 . Known contraindication anticoagulant include vitamin K antagonists warfarin 3 . Known suspected hereditary acquire bleed coagulation disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Anti-coagulant</keyword>
	<keyword>Non-valvular</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Prevention Blood Clots</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Non-valvular atrial fibrillation</keyword>
</DOC>